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Abstract
Sickle cell disease (SCD) is the most common life-limiting genetic disease among African Americans, affecting more
than 100,000 people in the United States. Respiratory disorders in patients with sickle cell disease have been associated
with increased morbidity and mortality. Associations between asthma and pain, acute chest syndrome (ACS), and even
death have long been reported. More recently wheezing, even in the absence of an asthma diagnosis, has gained
attention as a possible marker of SCD severity. Several challenges exist with regards to making the diagnosis of
asthma in patients with SCD, including the high prevalence of wheezing, evidence of airway obstruction on pulmonary
function testing, and/or airway hyperresponsiveness among patients with SCD. These features often occur in isolation,
in the absence of other clinical criteria necessary for an asthma diagnosis. In this review we will summarize: 1) Our current
understanding of the epidemiology of asthma, wheezing, airway obstruction, and airway responsiveness among patients
with SCD; 2) The evidence supporting associations with SCD morbidity; 3) Our understanding of the pathophysiology of
airway inflammation in SCD; 4) Current approaches to diagnosis and management of asthma in SCD; and 5) Future
directions.
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Background
Sickle cell disease (SCD) is the most common life-limiting
genetic disease among African Americans, affecting more
than 100,000 people in the United States [1]. Respiratory
disorders in patients with sickle cell disease have been as-
sociated with increased morbidity and mortality. Associa-
tions between asthma and pain, acute chest syndrome
(ACS), and even death have long been reported. More re-
cently wheezing, even in the absence of an asthma diagno-
sis, has gained attention as a possible marker of SCD
severity. In this review we will summarize: 1) Our current
understanding of the epidemiology of asthma, wheezing,
airway obstruction, and airway responsiveness among pa-
tients with sickle cell disease; 2) The evidence supporting
associations with SCD morbidity; 3) Our understanding of
the pathophysiology of airway inflammation in SCD; 4)
Current treatment options; and 5) Future directions.
Asthma in SCD: why all the fuss?
Asthma is the most common chronic disease of childhood,
and African Americans are disproportionately affected. Re-
cent US data demonstrate an asthma prevalence of 15 %
among African American children versus 8 % among Cau-
casian children [2]. Thus, we can extrapolate that a sub-
stantial percentage of children with SCD are going to have
asthma. In the past decade, there have been studies sug-
gesting that 1) asthma occurs at a similar frequency among
African Americans with and without SCD [3–5], although
two separate studies suggest that asthma may be more
common among those with SCD compared to those with-
out; [6, 7] 2) those who have SCD and asthma have higher
rates of vaso-occlusive morbidity (pain and ACS episodes)
compared to those with SCD and no asthma; [3, 5, 6, 8]
and 3) asthma is a risk factor for mortality in SCD [9, 10].
Several questions exist with regards to these epidemio-
logic associations. For the question of asthma prevalence in
SCD, there has been no population-based study of individ-
uals with SCD compared to a comparable population with-
out any underlying disease. The best available data are from
prospective studies of those with SCD who are generally
followed at academic tertiary care SCD centers and enrolled
irrespective of symptoms. Data gleaned from these cohorts
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are not necessarily representative of the SCD population at
large, making it difficult to truly understand the prevalence
of asthma in this population. The Cooperative Study of
SCD (CSSCD) was a longitudinal prospective cohort study
which began enrolling patients regardless of symptoms or
disease severity in 1978. Among 291 participants followed
from infancy until at least age 5 years (mean length of fol-
low up = 11 years) the prevalence of asthma was 17 % [5].
In addition to the CSSCD, the Sleep and Asthma Cohort
(SAC) Study, began enrolling 253 children 4–19 years of
age with sickle cell anemia (SCA, referring to those with
HbSS and HbSβ° genotypes) in 2004 and followed them
prospectively until 2014. The prevalence of asthma in the
well-characterized SAC cohort is 28 % [11]. However, the
asthma prevalence reported in SAC may not be truly repre-
sentative of the general population with SCD, as children
were enrolled from three tertiary care centers where clini-
cians may have had a particularly high index of suspicion
for asthma [12]. The Pulmonary Hypertension and Hypoxic
Response (PUSH) prospective cohort study enrolled 376
children age 3–20 years regardless of symptoms, and re-
ported an asthma prevalence of 24 % [13]. One cross-
sectional study conducted in Jamaica compared 80 children
with SCD to a control group of 80 non SCD children found
that 48 % of the SCD group had ever had “a touch of
asthma” compared to 22 % of the control group [6].
Second, and perhaps more important, is how asthma is
defined in these studies (Table 1). In the CSSCD cohort
where associations between asthma and pain, ACS, and
mortality were noted, asthma is defined as a personal or
parental report of a physician diagnosis of asthma. Other
studies that conclude asthma is a risk factor for morbidity
use a similar definition, which is fairly standard for epide-
miologic studies of asthma [14–16]. The PUSH study de-
fined “asthma” as the presence of a report of “medical
history of asthma or wheezing” without review of the
medical record, [17] while SAC defined “asthma “ as a par-
ent report of a physician diagnosis plus the use of a con-
troller medication, confirmed by review of the medical
record [3]. The big question that many of us are trying to
answer is “What exactly IS asthma in SCD? How do we
know it when we see it?” Part of the challenge for clini-
cians caring for SCD patients is that many of the common
features of asthma – wheezing, airway obstruction, and
even airway hyperresponsiveness during a bronchoprovo-
cation challenge – are common in SCD but occur in isola-
tion without other supporting evidence to warrant an
asthma diagnosis. We explore these concepts further in
the following sections.
Wheezing: common in SCD and independently associated
with morbidity
Wheezing is a common clinical finding among SCD pa-
tients. Data from 1722 ACS episodes that occurred in the
CSSCD cohort, demonstrated wheezing in 11 % of patients
upon admission to the hospital, and was ultimately present
in 26 % during the course of the ACS episode. Wheezing
was equally common among children and adults [18]. In a
second multicenter study of 538 patients with 671 episodes
of ACS, wheezing was detected during 26 % of ACS epi-
sodes [19]. In a retrospective cohort study of 262 children
with SCD who presented to an urban emergency depart-
ment over a 4 year period, 19 % had at least one presenta-
tion in which wheezing was documented, although fewer
than half of those children carried an asthma diagnosis
[20]. In an unselected single center cohort of 114 adults,
30 % had at least two recurrent episodes of wheezing lead-
ing to shortness of breath, of whom almost half did not
have a diagnosis of asthma [21]. Investigating which SCD
patients with observed wheezing should have actually been
diagnosed with asthma remains an area for future study.
Wheezing, without a co-existing diagnosis of asthma,
has been associated with SCD morbidity in both children
and adults. Among 159 children with SCA, DeBaun et al.
found that a parental report of an episode of wheezing
producing shortness of breath was associated with in-
creased risk of a future episode of ACS (IRR 1.7, p = 0.04)
during a median 5.2 years of follow-up [22]. In a prospect-
ive cohort of 262 patients with SCD (aged 6–68 years)
seen in the Emergency Department, documentation of
wheezing on physical exam (irrespective of asthma) was
associated with more than two times the incidence of fu-
ture vasoocclusive and ACS episodes during a 4 year
follow-up period [20]. In the aforementioned mentioned
study of 114 adults with SCD, while physician-diagnosed
asthma was not associated with either increased rates of
pain or ACS, 2 or more episodes of severe wheezing was
associated with approximately a twofold increase of both
vasoocclusive and ACS episodes as well as increased risk
of early death (HR 4.2, 95 % CI 1.0–17.5, p < 0.05) [21]. Fi-
nally, in addition to prior studies showing respiratory
symptoms in known asthmatics precede vaso-occlusive
crises, [23, 24] recent evidence suggests a temporal rela-
tionship between respiratory symptoms including wheez-
ing and SCD morbidity even in the absence of asthma. In
a mostly adult SCD cohort (mean age 29 years) of 47 par-
ticipants in whom asthma was ruled out via a prospective
multistep algorithm that included participant report and
medical record review, researchers conducted repeated
telephone questionnaire interviews to ascertain the pres-
ence of cough or wheeze during consecutive 8 week pe-
riods over a mean of 9 months of follow-up. 68 % of
participants reported at least one episode of cough or
wheeze during the follow-up period, usually in the setting
of colds; report of cough and/or wheeze symptoms during
one 8 week period was associated with a two-fold in-
creased rate of ED visits for pain in the subsequent 8 week
period [25].
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Table 1 Summary of studies reporting prevalence of asthma in SCD patients
Study (year) Study design SCD type Ages How defined Prevalence (%)
Boyd et al. (2006) [5] CSSCD: 291 children enrolled
in prospective cohort study
HbSS Enrolled <6 months
and followed through
>5 years
Parent report of physician diagnosis of asthma 17 %
Rosen et al. (2014) [11] SAC: 243 children in a
prospective cohort study
HbSS or HbSβ0 4–19 years Physician diagnosis of asthma and use of asthma
medication ever, via parent report and confirmed
with chart review [3]
28 %
Knight-Madden et al. (2005) [6] Case control study of 80 children
with SCD from Jamaica with 80
age, ethnic matched controls
HbSS 5–10 years Parent report using modified ISAAC questionnaire
(“touch of asthma”) for “lifetime asthma;” and
wheeze or cough in past 12 months lasting 7
days in absence of URI for “current asthma”
48 % asthma ever,
41 % current asthma
Paul et al. (2013) [13] PUSH: 503 children with SCD
in a prospective cohort study
All types 3–20 years Parent answers yes to question “medical
history of asthma or wheezing” [17]
24 %
Cohen et al. (2011) [21] 114 adults with SCD in a
prospective cohort study
All types 18–72 years Positive response to the ATS-DLD question
“Has a doctor ever diagnosed you with asthma”
















Airway obstruction: common in SCD
Airway obstruction has been reported to be common
among children with SCD, and has been demonstrated as
early as infancy. Koumbourlis et al. performed infant pul-
monary function tests with 20 SCD infants (including 12
with HbSS and 8 with mixed heterozygous hemoglobinop-
athies) and found elevated functional residual capacities
(FRC), decreased maximum expiratory flows at FRC, and
decreased time at maximum expiratory flows relative to
the total expiratory time, suggesting hyperinflation and
lower airway obstruction [26] Their group then studied 61
children age 5–18 years with HbSS and reported a 35 %
prevalence of lower airway obstruction, [27] though their
definition of an obstructive pattern (FEV1/FVC < 0.85,
scooping of the flow/volume curve, and a “disproportion-
ately low FEF25–75 % predicted”) [28] differs from the
current ATS/ERS guidelines [29]. In the prospective, lon-
gitudinal PUSH study, 97 participants with HbSS or
HbSβ° age 7–20 years completed spirometry and plethys-
mography for lung function classification. 18 children
(19 %) met criteria for obstruction, defined as having
an FEV1/FVC ratio and either an FEV1 or FEF25–75
below the lower limit of normal. Forty-four percent of
those with obstruction (N = 8) had a history of asthma
or wheezing [17].
The significance of lower airway obstruction in SCD is
not well understood. In a single institution, referred clinic
cohort of 102 children with SCD, lower airway obstruction
(defined by the standard ATS/ERS definition of an FEV1/
FVC ratio <95 % CI for age, gender, and height [30]) was
associated with twice the prospective rate of pain com-
pared to those with normal lung function (IRR 2.16 (1.08–
4.26); P = 0.027) [31]. A second retrospective chart review
study of 127 patients concluded that a history of ACS
events was associated with having lower airway obstruction
on spirometry, but the definition of obstruction in that
study was single cut-off for the FEV1/FVC ratio (85 %) ra-
ther than using the current ATS/ERS guidelines [32]. Fur-
ther longitudinal research is needed to investigate
associations between appropriately defined lower airway
obstruction and SCD morbidity (i.e., do ACS events in
childhood impact lung function in adulthoods? Is airway
obstruction associated with future risk of SCD morbidity?).
Airway hyperresponsiveness: common in SCD, but does it
matter?
There are several small cross sectional studies that show
a high prevalence of airway hyperresponsiveness in SCD
(Table 2). In several small pediatric studies with sample
sizes ranging from 21–40 children, airway hyperrespon-
siveness (AHR) to cold air or methacholine was present
in 14–77 % of children with SCD [33–36]. In similar
small studies of adults, prevalence of AHR ranged from
31–48 %, three to four fold higher than among control
subjects in those studies [37, 38]. Given these small sam-
ple sizes, the Sleep and Asthma Cohort research group
sought to establish the prevalence of AHR to methacho-
line in their unselected cohort of 243 children with SCA.
When the 99th participant in the study (age = 14 years)
was hospitalized for his first ever vaso-occlusive crisis
following his methacholine challenge, [39] the SAC
group removed methacholine challenge testing from
their protocol. Among the 99 participants who had
completed that methacholine testing, 55 had a PC20 <
4 mg/ml [40].
The significance of the increased prevalence of airway
reactivity to methacholine among SCD patients is not
well understood. In a pulmonary function and biomarker
study of 50 children with SCD and 50 non-SCD con-
trols, Chaudry et al. found no difference in the metha-
choline dose response slope (DRS [defined as the % drop
in FEV1 per increasing dose of methacholine]) between
children with SCD versus controls, but did find that the
DRS was higher among children with an asthma diagno-
sis than those without (4.46 vs 0.64, p = 0.006) regardless
of their SCD status. That said, in multivariable models,
DRS was not associated with FEV1, FEV1/FVC, fractional
exhaled nitric oxide (FeNO) levels, or IgE among the
SCD group [41]. Similarly, among the 99 children with
SCA in SAC, the DRS was not associated with FEV1,
FEV1/FVC, or FeNO, and was not associated with having
an asthma diagnosis, bronchodilator responsiveness, hav-
ing positive allergy skin tests, or the peripheral eosinophil
count. DRS was, however, associated with increased serum
IgE and lactate dehydrogenase (LDH) levels, reflective
possibly of increased atopy and hemolysis respectively
[40]. The association between methacholine DRS with
LDH suggests a unique mechanism of AHR in SCD pa-
tients that may be more reflective of SCD pathogenesis
than atopy.
Data are conflicting regarding whether airway respon-
siveness is independently associated with SCD morbid-
ity. Chaudry found no differences in the DRS between
those with the more severe HbSS and the milder HbSC
genotypes [41]. In terms of whether prior history of ACS
is associated with current AHR, Ozbek et al. found that
the difference in PC20 results between those with and
without a history of ACS did not reach significance (0.64
vs. 3.28 mg/ml, p = 0.06), though this may have been a
function of sample size [36]. Sylvester et al. found no
between-group differences in % drop in FEV1 after cold
air challenge between those with and without ACS (me-
dian drop of 2.8 % in both groups), and that among the
6 children with a positive cold air challenge, none had a
prior history of ACS [33]. In contrast, in a small adult
cohort of 31 adults with SCD, there was a significant
correlation between the number of retrospective ACS
events and the methacholine PC20 [38].
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Table 2 Summary of studies addressing prevalence and clinical correlates of airway hyperresponsiveness in children and adults with SCD
Study (year) Study design Ages Prevalence of AHR Clinical Correlates of AHR
Leong et al. (1997) [34] Cold air challenge in 32
children with SCD
6–19 years 67 % with 10 % drop in FEV1 No difference in prevalence of AHR to cold air
between SCD patients with and without asthma;
Sylvester et al. (2007) [33] Cold air challenge in 42
children with HbSS
6–16 years 14 % with 10 % drop in FEV1 No association between prior history of ACS
and likelihood of having a positive cold air
challenge test
Strunk et al. (2008) [35] MCT in 21 clinically referred
children with SCD and
respiratory symptoms
5–18 years 67 % with PC20 < 12.5 mg/ml Not evaluated
Ozbek et al. (2007) [36] MCT in 31 children 6–16 years 77 % with PC20 < 16 mg/ml, 58
% with PC20 < 1 mg/ml
No differences in PC20 between those with
and without history of ACS (p = 0.06)
Field et al. (2011) [40] MCT in 99 children with
HbSS or HbSβ0
55 % with PC20 < 4 mg/ml Methacholine DRS not associated with STR,
BDR, peripheral blood eosinophil count, or
asthma diagnosis; DRS was associated with
serum IgE and LDH
Chaudry et al. (2014) [41] Cohort study 50 children
with SCD and 50 non-SCD
controls, 93 completed MCT
10–18 years Prevalence of PC20 below a specified
threshold not reported;
No difference in DRS between those DRS
higher in children with asthma in both groups;
No differences in DRS between HbSS and HbSC;
DRS not associated with FEV1, FEV1/FVC, FeNO,
or IGE among the SCD group;
Vendramini et al. (2006) [37] MCT in 26 adults with and
28 controls without SCD
18–41 years PC20 < 16 mg/ml in 31 % of
SCD, 7 % of controls
Positive methacholine challenge not associated
with having a baseline obstructive pattern
on spirometry
Sen et al. (2009) [38] MCT in 31 adults with SCD 18–44 years 48 % with PC20 < 16 mg/ml, 42 %
with PC20 < 4 mg/ml
Significant association between the number
of retrospective ACS events and having a
positive methacholine challenge
Abbreviations: ACS acute chest syndrome, BDR bronchodilator responsiveness, DRS dose response slope, MCT methacholine challenge test, PC20 provocative concentration dose associated with a 20 % drop in FEV1;















Other asthma features and SCD: markers of atopy and
family history of asthma: their relationship to asthma and
to SCD morbidity
Given the association between an asthma “diagnosis”
and SCD morbidity juxtaposed with the frequency with
which children with SCD have wheezing, airway ob-
struction, and/or airway hyperresponsiveness, investi-
gators have started to investigate whether other factors
that have been related to asthma in non-SCD children
could help to diagnose asthma in SCD. Studies looking
at whether IgE levels can be used to discriminate be-
tween those with and without asthma have been incon-
sistent. While some studies have demonstrated that
children and adults with SCD and asthma have higher
IgE levels than those without asthma, [21, 42, 43]
Strunk et al. found that there was no difference in IgE
levels between those with and without a physician
diagnosis of asthma among children in the SAC cohort
[3]. Having ≥ 2 positive skin tests to aeroallergens was
more common among those with asthma compared to
those without asthma in the SAC cohort, but skin test
reactivity did not add much to a predictive model for
discriminating “asthma” from “no asthma” in this co-
hort [3]. Ross et al. reported that SCD children with an
asthma diagnosis were more likely to have positive
ImmunoCAP testing to a 6-item food allergy panel
than children without asthma (61 % vs. 35 %, p =
0.002) [43]. In terms of family history, a parental his-
tory of asthma was one of the most important features
discriminating children with a physician diagnosis of
asthma from children without asthma [3]. Data from
211 children in the CSSCD cohort demonstrated that
having a first degree family relative with asthma was a
significant risk factor for a personal history of asthma
(odds ratio 6.4, 95 % CI 2.8 to 14.1, p < .001). While
parental history of asthma was not associated with in-
creased rates of pain or ACS, sibling history of asthma
was independently associated with increased risk of
VOC, even after adjusting for personal history of an
asthma diagnosis (adjusted IRR 1.91, 95 % CI 1.18 to
3.09, P = 0.008) [44].
Atopic features have been associated with SCD mor-
bidity. In a cohort of 80 Jamaican children with SCD,
having at least one positive allergy skin prick test was
associated with significantly increased odds of having
“recurrent” ACS (≥2 episodes, OR 4.8, 95 % C.I. 1.5–
16.1, p < 0.01) [6]. Among 521 children with SCD in
the Silent Cerebral Infarct Trial, both an asthma diag-
nosis and elevated total serum IgE levels were inde-
pendently associated with increased rates of ACS
events [42]. DeBaun et al. found that having 2 or more
positive allergy skin tests was an independent risk fac-
tor for future ACS events (IRR 1.87, 95 % CI 1.16-3.00,
p = 0.01) [22].
What is known about mechanisms of airway disease in SCD?
Animal models of SCD have an exaggerated inflamma-
tory response. Nandedkar et al. compared mice express-
ing normal human (HbA) or normal murine (Wild type
or WT) hemoglobin to transgenic SCD mice. Mice were
sensitized to ovalbumin to induce lung inflammation,
had a two week recovery period, and then received ei-
ther high (“HiSen”) or low (“LoSen”) levels of an inhaled
ovalbumin challenge daily for 10 days. 10 % of the SCD
mice died during the recovery period prior to initiation
of the inhalation challenges, compared to no deaths in
the control mice groups. SCD LoSen mice had more air-
way eosinophilia than HbA or WT LoSen mice, and the
SCD HiSen mice had higher IgE levels than WT or HbA
mice suggesting increased inflammation. Furthermore,
during the inhalation challenge period, 10 % of the
LoSen and 30 % of the HiSen SCD mice died, compared
with 4 % of the HbA mice and none of the WT mice,
suggesting an impact of inflammation on SCD mortality
[45]. In a second study, the same group found that
chimeric SCD mice had a higher baseline leukocytosis
and IL-13 levels compared with chimeric HbA mice.
Following induction of experimental asthma by ovalbu-
min sensitization, chimeric SCD mice had dramatically
increased IL-5 expression, greater airway resistance in
the large and small airways, and greater airway respon-
siveness to methacholine compared to HbA mice, fur-
ther demonstrating a greater baseline inflammatory
profile and subsequent exaggerated airway inflamma-
tion among SCD mice [46]. In a more recent study,
unsensitized SCD mice had increased perivascular in-
flammation and evidence of an increased Th2 response
including increased total lymphocytes, CD8+ T cells,
and CD4+ T cells (with increased total Treg cells) and
increased levels of IL-5 when compared to control
mice. SCD mice also had more robust responses to ov-
albumin in terms of BAL leukocytosis and eosinophilia,
higher levels of ovalbumin-specific serum IgE levels,
and increased expression of IL-6 and 13 compared to
control mice. Interestingly and in contrast to the previ-
ously described study, [46] ovalbumin-sensitized SCD
mice had less airway hyperresponsiveness to methacholine
than did control mice despite the observed enhanced in-
flammatory response. The authors hypothesize that this
finding could indicate that airway obstruction may not be
due to methacholine-induced bronchoconstriction (and
thus, less responsive to conventional asthma therapies)
but due to alternative SCD-specific mechanisms [47].
Not all studies support the notion that there is an in-
creased Th2 response in SCD. Knight-Madden and col-
leagues compared cytokine profiles in 80 children with
SCD in Jamaica and 53 children with SCD in the United
Kingdom to cytokine profiles among local healthy con-
trols. Children with SCD in Jamaica were more likely to
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have asthma and more likely to have increased Th2 cyto-
kines (defined as detectable IL-4/undetectable IFN- γ)
than local Jamaican age- and ethnically- matched con-
trols while children in the UK with SCD were less likely
to have asthma and increased Th2 cytokines than local
controls [48]. This discrepancy was attributed to tropical
increases in helminth exposure among the Jamaican
children, which promotes a Th2 inflammatory response
that may have been particularly exaggerated among the
children with SCD [48].
Exhaled nitric oxide (eNO) levels have been examined
in patients with SCD. In the general population and in
cohorts of children with asthma, eNO has been used as
a marker of airway inflammation– and has been associ-
ated with several features of atopic asthma such as total
serum IgE, peripheral blood eosinophilia, and the FEV1/
FVC ratio in children with asthma [49, 50]. Studies have
demonstrated eNO levels in children with SCD to be
lower, [51] higher, [52] or the same [41, 53] as eNO levels
in healthy controls. Chaudry et al. compared features of
airway function in 50 children with SCD to 50 healthy
controls. They found that eNO levels were higher in
atopic children compared to those without atopy across
both the SCD and control groups, but eNO was not corre-
lated with the degree of airway responsiveness to metha-
choline among the SCD group [41]. Whether or not eNO
measurements can be used as a tool to aide in deciding
which children with SCD do or do not have asthma has
not been thoroughly investigated. Data from methods of
measuring airway inflammation, such as measuring the
degree of eosinophilia or neutrophilia from induced spu-
tum, are also lacking.
More recently, investigators have emphasized the role
of vascular factors on obstructive airway phenotypes in
SCD. In a British study of 25 children with HbSS and
25 age- and ethnic- matched controls, the children with
SCD had greater pulmonary capillary blood volume and
increased respiratory system resistance (R5 % predicted,
as measured by impulse oscillometry) compared to con-
trols. Among the children with HbSS only, pulmonary
capillary blood volume was positively correlated with
R5 and the ratio of residual volume/total lung capacity
(RV/TLC), and negatively correlated with FEV1 and
mean maximal expiratory flow (MMEF 25–75) suggest-
ing that airway obstruction in SCD may be related to
increased cardiac output and increased pulmonary
blood volume in response to chronic anemia [54]. The
same group of investigators obtained high resolution
computed tomography (HRCT), echocardiograms, and
pulmonary function tests in 35 adults with SCD and
found associations between increased cardiac output on
echocardiography, increased pulmonary artery/bron-
chus ratios on HRCT, increased respiratory system re-
sistance, increased RV/TLC, and decreased FEV1 and
FEF25–75 supporting the notion that abnormalities in
pulmonary vascular volumes have effects on airway
function in patients with SCD which are independent
of asthma [55].
How do we put it all together?
Wheezing is common in SCD, and may or may not be
associated with a diagnosis of asthma in this population.
Airway obstruction and airway reactivity are also com-
mon but are also poor indicators of asthma in SCD.
Both wheezing and pulmonary function test evidence of
airway abnormalities may be important markers of SCD
severity. The most recent version of the NHLBI guide-
lines on the Evidence-Based Management of Sickle Cell
Disease make the following recommendations: 1) assess
for signs and symptoms of respiratory problems by his-
tory and physical examination; 2) in patients with signs
or symptoms of respiratory problems, further assess-
ment (including pulmonary function testing) is recom-
mended; and 3) in otherwise asymptomatic individuals,
screening pulmonary function testing is NOT recom-
mended [56]. The recommendation against screening
all individuals for abnormal pulmonary function is
based on the paucity of evidence that pulmonary func-
tion screening offers clinical benefit or is cost-effective.
To date, there have been no published studies regarding
interventions targeted towards individuals with abnor-
mal lung function.
We recommend the following for all patients with SCD:
1. Careful symptom screening with a high index of
suspicion for: history of wheezing, atopy, family
history of asthma, and any history of dyspnea or
exercise limitation.
2. Any patient positive for the above historical features
should be referred for evaluation with a pulmonologist
including pulmonary function testing.
3. Consider allergy testing if symptoms suggest that
sensitization to environmental exposures could be
exacerbating symptoms.
4. Optimization of SCD management in consultation
with a hematologist including consideration of
hydroxyurea, currently the only FDA-approved
therapy for the management of SCD which reduces
morbidity and mortality in these patients.
5. In patients for whom a diagnosis of persistent
asthma seems appropriate based on history (repeated
episodes of wheezing and cough in response to known
triggers, clinical response to bronchodilators, and
other historical features consistent with asthma
including personal and family history of atopy and
first degree relative with asthma), treatment with
anti-inflammatory controller therapy according to the
NHLBI guidelines is recommended [3, 57].
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Conclusions and future directions
Wheezing and airway function abnormalities are common
in SCD, but as is true in the general population, “all that
wheezes is not asthma.” We first need a better understand-
ing of the mechanisms underlying these common clinical
features so that we can differentiate asthma from what
Knight-Madden and Greenough have termed “Recurrent
Wheezing in Sickle Cell Disease (RWIS)” [58]. Once we
have a better understanding of the mechanisms underlying
airway abnormalities in SCD we can begin to explore the
impact of therapeutic interventions on recurrent wheezing,
airway obstruction, and/or asthma on short and long term
SCD outcomes. This is an important, understudied area
that warrants further investigation in an attempt to reduce
morbidity and mortality in these patients.
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Hypoxic Response study; SAC: Sleep and Asthma Cohort study; SCA: Sickle
cell anemia; SCD: Sickle cell disease.
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